Patents by Inventor Todd Waldman

Todd Waldman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STROMAL ANTIGEN 2 (STAG2) COMPOSITIONS AND METHODS
    Publication number: 20140094384
    Abstract: Compositions and methods related to stromal antigen 2 (STAG2) and its role in diverse human cancers, including nucleic acids, polypeptides, vectors, cells and cell lines.
    Type: Application
    Filed: November 25, 2013
    Publication date: April 3, 2014
    Applicant: Georgetown University
    Inventors: David SOLOMON, Jung-Sik Kim, Todd Waldman
  • Stromal Antigen 2 (STAG2) Compositions and Methods
    Publication number: 20130216559
    Abstract: Compositions and methods related to stromal antigen 2 (STAG2) and its role in diverse human cancers, including nucleic acids, polypeptides, vectors, cells and cell lines.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 22, 2013
    Applicant: GEORGETOWN UNIVERSITY
    Inventors: TODD WALDMAN, DAVID SOLOMON, JUNG-SIK KIM
  • Stromal Antigen 2 (STAG2) Compositions and Methods
    Publication number: 20130029865
    Abstract: Compositions and methods related to stromal antigen 2 (STAG2) and its role in diverse human cancers, including nucleic acids, polypeptides, vectors, cells and cell lines.
    Type: Application
    Filed: July 12, 2012
    Publication date: January 31, 2013
    Applicant: Georgetown University
    Inventors: David SOLOMON, Jung-Sik Kim, Todd Waldman
  • Cancer drug screen based on cell cycle uncoupling
    Patent number: 7148009
    Abstract: Checkpoint gene-defective human cells are useful for screening potential anti-tumor agents. Potential therapeutic agents are screened for the ability to cause DNA accumulation or cell death in a checkpoint gene-defective human cell.
    Type: Grant
    Filed: December 17, 2002
    Date of Patent: December 12, 2006
    Assignee: The Johns Hopkins University
    Inventors: Bert Vogelstein, Todd Waldman, Christoph Lengauer, Kenneth W. Kinzler
  • Isogenic beta-catenin cell lines, and methods of making and using same
    Publication number: 20050208652
    Abstract: A set of isogenic cell lines, which includes a first population of cells that express only a wild type ?-catenin polypeptide and at least a second population of cells that express only an activated ?-catenin polypeptide, is provided. A set of isogenic cells, including a first population of cells that are null for ?-catenin expression, and at least a second population of cells that express a wild type ?-catenin polypeptide that functions as an activated ?-catenin polypeptide in the cells, also is provided. In addition, a recombinant nucleic acid molecule, which includes at least a first linear polynucleotide that is flanked at each end by nucleotide sequences of a ?-catenin gene is provided, as is a method of using the recombinant nucleic acid molecule to produce a set of isogenic cell lines as defined above.
    Type: Application
    Filed: April 11, 2005
    Publication date: September 22, 2005
    Inventor: Todd Waldman
  • Novel cancer drug screen based on cell cycle uncoupling
    Publication number: 20030108941
    Abstract: Checkpoint gene-defective human cells are useful for screening potential anti-tumor agents. Potential therapeutic agents are screened for the ability to cause DNA accumulation or cell death in a checkpoint gene-defective human cell.
    Type: Application
    Filed: December 17, 2002
    Publication date: June 12, 2003
    Applicant: The Johns Hopkins University
    Inventors: Bert Vogelstein, Todd Waldman, Christoph Lengauer, Kenneth W. Kinzler
  • Cancer drug screen based on cell cycle uncoupling
    Patent number: 6511818
    Abstract: Checkpoint gene-defective human cells are useful for screening potential anti-tumor agents. Potential therapeutic agents are screened for the ability to cause DNA accumulation or cell death in a checkpoint gene-defective human cell.
    Type: Grant
    Filed: April 10, 2001
    Date of Patent: January 28, 2003
    Assignee: The Johns Hopkins University
    Inventors: Bert Vogelstein, Todd Waldman, Christoph Lengauer, Kenneth W. Kinzler
  • Isogenic beta-catenin cell lines, and methods of making and using same
    Publication number: 20020132340
    Abstract: A set of isogenic cell lines, which includes a first population of cells that express only a wild type &bgr;-catenin polypeptide and at least a second population of cells that express only an activated &bgr;-catenin polypeptide, is provided. A set of isogenic cells, including a first population of cells that are null for &bgr;-catenin expression, and at least a second population of cells that express a wild type &bgr;-catenin polypeptide that functions as an activated &bgr;-catenin polypeptide in the cells, also is provided. In addition, a recombinant nucleic acid molecule, which includes at least a first linear polynucleotide that is flanked at each end by nucleotide sequences of a &bgr;-catenin gene is provided, as is a method of using the recombinant nucleic acid molecule to produce a set of isogenic cell lines as defined above.
    Type: Application
    Filed: March 7, 2002
    Publication date: September 19, 2002
    Inventor: Todd Waldman
  • Novel cancer drug screen based on cell cycle uncoupling
    Publication number: 20010012619
    Abstract: Checkpoint gene-defective human cells are useful for screening potential anti-tumor agents. Potential therapeutic agents are screened for the ability to cause DNA accumulation or cell death in a checkpoint gene-defective human cell.
    Type: Application
    Filed: April 10, 2001
    Publication date: August 9, 2001
    Inventors: Bert Vogelstein, Todd Waldman, Christoph Lengauer, Kenneth W. Kinzler
  • Homozygous p53 gene-defective human colonic cell line
    Patent number: 6214616
    Abstract: Checkpoint gene-defective human cells are useful for screening potential anti-tumor agents. Potential therapeutic agents are screened for the ability to cause DNA accumulation or cell death in a checkpoint gene-defective human cell.
    Type: Grant
    Filed: April 26, 1999
    Date of Patent: April 10, 2001
    Assignee: The Johns Hopkins University
    Inventors: Bert Vogelstein, Todd Waldman, Kenneth W. Kinzler
  • Cancer drug screen based on cell cycle uncoupling
    Patent number: 5897999
    Abstract: Checkpoint gene-defective human cells are useful for screening potential anti-tumor agents. Potential therapeutic agents are screened for the ability to cause DNA accumulation or cell death in a checkpoint gene-defective human cell.
    Type: Grant
    Filed: March 22, 1996
    Date of Patent: April 27, 1999
    Assignee: The Johns Hopkins University
    Inventors: Bert Vogelstein, Todd Waldman, Kenneth W. Kinzler
  • Cancer drug screen based on cell cycle uncoupling
    Patent number: 5888735
    Abstract: Checkpoint gene-defective human cells are useful for screening potential anti-tumor agents. Potential therapeutic agents are screened for the ability to cause DNA accumulation or cell death in a checkpoint gene-defective human cell.
    Type: Grant
    Filed: January 10, 1997
    Date of Patent: March 30, 1999
    Assignee: The Johns Hopkins University
    Inventors: Bert Vogelstein, Todd Waldman, Christoph Lengauer, Kenneth W. Kinzler
  • Cancer drug screen based on cell cycle uncoupling
    Patent number: 5882865
    Abstract: Checkpoint gene-defective human cells are useful for screening potential anti-tumor agents. Potential therapeutic agents are screened for the ability to cause DNA accumulation or cell death in a checkpoint gene-defective human cell.
    Type: Grant
    Filed: January 10, 1997
    Date of Patent: March 16, 1999
    Assignee: The Johns Hopkins University
    Inventors: Bert Vogelstein, Todd Waldman, Christoph Lengauer, Kenneth W. Kinzler
  • Cancer drug screen based on cell cycle upcoupling
    Patent number: 5879889
    Abstract: Checkpoint gene-defective human cells are useful for screening potential anti-tumor agents. Potential therapeutic agents are screened for the ability to cause DNA accumulation or cell death in a checkpoint gene-defective human cell.
    Type: Grant
    Filed: January 10, 1997
    Date of Patent: March 9, 1999
    Assignee: The Johns Hopkins University
    Inventors: Bert Vogelstein, Todd Waldman, Christoph Lengauer, Kenneth W. Kinzler